Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Item
http://www.wikidata.org/entity/Q40050396
Response to Harper and De Mars, HPV vaccines: A review of the first decade.Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.9-Valent human papillomavirus vaccine: a review of the clinical development program.Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.Major clinical research advances in gynecologic cancer in 2017.Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical MalignancyDirect, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain
P2860

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Item
http://www.wikidata.org/entity/Q40050396
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Final efficacy, immunogenicity ...... andomised, double-blind trial.
@en
type
label
Final efficacy, immunogenicity ...... andomised, double-blind trial.
@en
prefLabel
Final efficacy, immunogenicity ...... andomised, double-blind trial.
@en
P1433
P1476
P2093
P31
P356
P407
P50
P577
P698
P356
P1433
P1476
Final efficacy, immunogenicity ...... andomised, double-blind trial.
@en
P2093
P31
P356
10.1016/S0140-6736(17)31821-4
P407
P50
P577
P698